Chordate Medical (“Chordate”, the “Company”) has entered into an agreement with one of Saudi Arabia’s leading medical device companies, Janin Medical Company (“Janin”), under which Janin will become the exclusive distributor in the Kingdoms of Saudi Arabia and Bahrain for both the migraine and rhinitis indications as of the turn of the year 2022/2023.
The venture in Saudi Arabia and the rest of the Gulf region is led by Chordate’s Regional General Manager Alain Durante. The focus for some time has been to establish the right market channel to successfully introduce the company’s K.O.S product for the treatment of migraine and rhinitis, which has now resulted in an exclusive distribution agreement with Janin Medical Company in Riyadh.
Janin is a privately held company established in 1996 and based in Riyadh with a local office in Jeddah. The company has a turnover of approximately SEK 25 million and a historically good profitability. The company is a focused importer and distributor of advanced medical devices in neurology, pulmonary medicine, cardiology, speech therapy/audiology and urology. Janin also has the status to bid for public tenders.
“We see Janin’s sales targeting neurologists as a good match, they have an established product portfolio and access to all major hospitals and government agencies in the country. With active support from our own representative in Saudi Arabia, this long-term cooperation will allow us to move the positions forward for our important migraine product as well,” says Anders Weilandt, CEO of Chordate.
More information about Janin Medical Company